HighTower Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

HighTower Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,088	Closed	-$475K	–	3915
2025 Q4	$475K	Buy	+11,088	New	+$418K	﹤0.01%	2672
2024 Q2	–	Sell	-887	Closed	-$13K	–	3869
2024 Q1	$13K	Buy	+887	New	+$12K	﹤0.01%	3386
2023 Q4	–	Sell	-1,015	Closed	-$11K	–	3820
2023 Q3	$11K	Buy	+1,015	New	+$12.2K	﹤0.01%	3381
2023 Q2	–	Sell	-1,715	Closed	-$22K	–	3640
2023 Q1	$22K	Buy	+1,715	New	+$27.2K	﹤0.01%	3140
2020 Q3	–	Sell	-1,051	Closed	-$19K	–	2666
2020 Q2	$19K	Hold	1,051	–	–	﹤0.01%	2269
2020 Q1	$17K	Buy	1,051 +10	+1%	+$213	﹤0.01%	2088
2019 Q4	$22K	Sell	1,041 -6	-0.6%	-$124	﹤0.01%	2161
2019 Q3	$20K	Hold	1,047	–	–	﹤0.01%	2278
2019 Q2	$27K	Sell	1,047 -40	-4%	-$903	﹤0.01%	2246
2019 Q1	$28K	Hold	1,087	–	–	﹤0.01%	2165
2018 Q4	$25K	Buy	1,087 +87	+9%	+$2.46K	﹤0.01%	2074
2018 Q3	$32K	Hold	1,000	–	–	﹤0.01%	2152
2018 Q2	$28K	Hold	1,000	–	–	﹤0.01%	2097
2018 Q1	$35K	Sell	1,000 -10	-1%	-$400	﹤0.01%	2034
2017 Q4	$39K	Buy	1,010 +10	+1%	+$381	﹤0.01%	2124
2017 Q3	$25K	Hold	1,000	–	–	﹤0.01%	2118
2017 Q2	$27K	Hold	1,000	–	–	﹤0.01%	2059
2017 Q1	$33K	Hold	1,000	–	–	﹤0.01%	1944
2016 Q4	$24K	Hold	1,000	–	–	﹤0.01%	1856
2016 Q3	$37K	Hold	1,000	–	–	﹤0.01%	1794
2016 Q2	$22K	Hold	1,000	–	–	﹤0.01%	1681
2016 Q1	$21K	Hold	1,000	–	–	﹤0.01%	2009
2015 Q4	$30K	Hold	1,000	–	–	﹤0.01%	1925
2015 Q3	$25K	Hold	1,000	–	–	﹤0.01%	1809
2015 Q2	$32K	Hold	1,000	–	–	﹤0.01%	1457
2015 Q1	$36K	Hold	1,000	–	–	﹤0.01%	1557
2014 Q4	$23K	Hold	1,000	–	–	﹤0.01%	1555
2014 Q3	$19K	Hold	1,000	–	–	﹤0.01%	1505
2014 Q2	$36K	Hold	1,000	–	–	﹤0.01%	1528
2014 Q1	$39K	Hold	1,000	–	–	﹤0.01%	1438
2013 Q4	$29K	Hold	1,000	–	–	﹤0.01%	1465
2013 Q3	$36K	Hold	1,000	–	–	﹤0.01%	1259
2013 Q2	$33K	Buy	+1,000	New	+$45.3K	﹤0.01%	1227

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's RIGL Position: Q1 2026 in Review

HighTower Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 11,088 shares — an estimated $475K sold.

HighTower Advisors first reported a position in RIGL in Q2 2013 and held it in 33 quarters. The position peaked at $475K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

HighTower Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HighTower Advisors sold 11,088 Rigel Pharmaceuticals shares in Q1 2026, an estimated $475K.
HighTower Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 33 quarters.
HighTower Advisors's Rigel Pharmaceuticals position peaked at $475K in Q4 2025.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.